Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Childhood unpredictability linked to higher mental health risks July 21, 2026 Researchers identify key factors for successful donor lymphocyte infusion in AML patients January 24, 2025 $10,000 experiment uncovers what makes us happiest January 1, 2025
Researchers identify key factors for successful donor lymphocyte infusion in AML patients January 24, 2025